These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19235630)

  • 1. Influence of molecular properties on oral bioavailability of lipophilic drugs - mapping of bulkiness and different measures of polarity.
    Kuentz MT; Arnold Y
    Pharm Dev Technol; 2009; 14(3):312-20. PubMed ID: 19235630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A; Hoffman A
    J Control Release; 2008 Jul; 129(1):1-10. PubMed ID: 18499294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diverse approaches for the enhancement of oral drug bioavailability.
    Fasinu P; Pillay V; Ndesendo VM; du Toit LC; Choonara YE
    Biopharm Drug Dispos; 2011 May; 32(4):185-209. PubMed ID: 21480294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the influence of cyclodextrins on oral absorption of low-solubility drugs: I. Model development.
    Gamsiz ED; Miller L; Thombre AG; Ahmed I; Carrier RL
    Biotechnol Bioeng; 2010 Feb; 105(2):409-20. PubMed ID: 19725042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADME evaluation in drug discovery. 6. Can oral bioavailability in humans be effectively predicted by simple molecular property-based rules?
    Hou T; Wang J; Zhang W; Xu X
    J Chem Inf Model; 2007; 47(2):460-3. PubMed ID: 17381169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancing intestinal drug solubilisation using lipid-based delivery systems.
    Porter CJ; Pouton CW; Cuine JF; Charman WN
    Adv Drug Deliv Rev; 2008 Mar; 60(6):673-91. PubMed ID: 18155801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selecting oral bioavailability enhancing formulations during drug discovery and development.
    Leucuta SE
    Expert Opin Drug Discov; 2014 Feb; 9(2):139-50. PubMed ID: 24387781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of cyclodextrins for enhancing oral bioavailability.
    Carrier RL; Miller LA; Ahmed I
    J Control Release; 2007 Nov; 123(2):78-99. PubMed ID: 17888540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs.
    Porter CJ; Trevaskis NL; Charman WN
    Nat Rev Drug Discov; 2007 Mar; 6(3):231-48. PubMed ID: 17330072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prodrug approaches for enhancing the bioavailability of drugs with low solubility.
    Müller CE
    Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating drug solubility in the gastrointestinal tract.
    Dressman JB; Vertzoni M; Goumas K; Reppas C
    Adv Drug Deliv Rev; 2007 Jul; 59(7):591-602. PubMed ID: 17599644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of gastrointestinal absorption of poorly water soluble drugs via lipid based systems.
    Subramanian N; Ghosal SK
    Indian J Exp Biol; 2004 Nov; 42(11):1056-65. PubMed ID: 15587110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
    Kuentz M; Imanidis G
    Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADME evaluation in drug discovery. 9. Prediction of oral bioavailability in humans based on molecular properties and structural fingerprints.
    Tian S; Li Y; Wang J; Zhang J; Hou T
    Mol Pharm; 2011 Jun; 8(3):841-51. PubMed ID: 21548635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic algorithm-optimized QSPR models for bioavailability, protein binding, and urinary excretion.
    Wang J; Krudy G; Xie XQ; Wu C; Holland G
    J Chem Inf Model; 2006; 46(6):2674-83. PubMed ID: 17125207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hologram QSAR model for the prediction of human oral bioavailability.
    Moda TL; Montanari CA; Andricopulo AD
    Bioorg Med Chem; 2007 Dec; 15(24):7738-45. PubMed ID: 17870541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The solubility of drugs in lipoid vehicles].
    Pflegel P; Klaus T; Schöbel H; Gruno M
    Pharmazie; 1993 Oct; 48(10):741-4. PubMed ID: 8265709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What determines drug solubility in lipid vehicles: is it predictable?
    Rane SS; Anderson BD
    Adv Drug Deliv Rev; 2008 Mar; 60(6):638-56. PubMed ID: 18089295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.